Slide 1: Q3 CellaVision Interim Report January-September 2024
Q3 CellaVision Interim Report January-September 2024 Strong Sales in EMEA Amid Market Uncertainties in the US Organic sales growth: Q3, 2024: 9% (11) EBITDA margin: Q3, 2024: 27% (26) July 1 – September 30, 2024 Net sales increased by 6% (19) to SEK 179 m (168). Sales increased organically 9% (11),
Slide 2: CEO's Comment
CEO’s Comment Building on the previous quarter’s success, Elsewhere, sales in the EMEA increased by 66 Finally, as we prepare to celebrate 30 years of CellaVision delivered solid revenue growth percent, reaching SEK 98 m (59), benefiting being committed to excellence and innovation in the third quar
Slide 3: Sales, Earning and Investments
Sales, Earning and Investments Net Sales and Currency Effects The gross margin is affected by purchase prices for materials inflation and a rise in consulting expenses, primarily related Net sales for the Group’s third quarter increased by 6 percent and components, the product mix, amortization of c
Slide 4: Investments and Cash Flow
Investments CellaVision continuously capitalizes expenses for product development. Capitalized development expenses amounted to SEK 14 m (12) during the quarter. The quarter’s total research and development expenses, before capitalization, amounted to SEK 40 m (36). For the nine-month period capital
Slide 5: Development in the Geographical Markets
Development in the Geographical Markets Americas: 69 m (87) EMEA: SEK 98 m (59) APAC: SEK 12 m (22) Sales in the Americas fell by 20 percent to SEK 69 m (87), Sales in EMEA surged by 66 percent to SEK 98 m (59) in In APAC, sales declined by 47 percent to SEK 12 m (22) compared to the corresponding q
Slide 6: Research and Development
Research and Development CellaVision’s ambition is to improve During the quarter, patents have been granted healthcare through continuous innovation. for two new inventions. One invention The company devotes considerable enables faster focusing when capturing images resources to research and develop
Slide 7: Annual General Meeting; Declaration by the Board of Directors and President/CEO
Annual General Meeting Annual General Meeting 2025 The CellaVision Annual General Meeting in 2025 will be held in Lund at 15:00 o´clock CEST, on May 6, 2025. Shareholders wishing to have matters considered at the Annual General Meeting can send a written request by email to: bolagsstamma@cellavision
Slide 8: Income Statement in Summary, Group
Income Statement in Summary and Consolidated Statement of Comprehensive Income, Group Amounts in ' 000 SEK Note Jul-Sep 2024 Jul-Sep 2023 Jan-Sep 2024 Jan-Sep 2023 Jan-Dec 2023 Net sales 4 178,656 167,895 536,529 476,660 677,292 Cost of goods sold -57,369 -56,471 -178,626 -149,541 -214,251 Gross pro
Slide 9: Per Share Data and Quarterly Earnings Trend
Per Share Data Per share data Jul-Sep 2024 Jul-Sep 2023 Jan-Sep 2024 Jan-Sep 2023 Jan-Dec 2023 Earnings per share, before and after dilution, SEK */ 1.30 1.09 4.18 3.35 5.46 Equity per share, SEK 32.19 28.42 32.19 28.42 30.04 Number of shares outstanding 23,851,547 23,851,547 23,851,547 23,851,547 2
Slide 10: Balance Sheet in Summary, Group; Changes in Equity
Balance Sheet in Summary, Group Amounts in ' 000 SEK Note 09/30/2024 09/30/2023 06/30/2024 12/31/2023 Assets Intangible assets 5 467,674 431,028 459,676 433,223 Tangible assets 6 119,581 124,750 122,580 125,502 Financial assets 7 3,034 4,976 3,883 4,396 Inventory 114,940 139,481 118,614 126,038 Trad
Slide 11: Cash Flow Statement in Summary, Group
Cash Flow Statement in Summary, Group Amounts in ' 000 SEK Jul-Sep 2024 Jul-Sep 2023 Jan-Sep 2024 Jan-Sep 2023 Jan-Dec 2023 Result before taxes 38,916 32,155 125,371 100,852 164,222 Adjustment for items not included in cash flow 16,386 13,884 47,463 39,020 49,382 Income tax paid -6,196 -5,458 -19,27
Slide 12: Income Statement in Summary, Parent Company
Income Statement in Summary and Consolidated Statement of Comprehensive Income, Parent Company Amounts in ' 000 SEK Jul-Sep 2024 Jul-Sep 2023 Jan-Sep 2024 Jan-Sep 2023 Jan-Dec 2023 Net sales 139,059 130,180 413,029 362,969 523,473 Cost of goods sold -33,498 -30,972 -104,372 -78,901 -118,814 Gross pr
Slide 13: Balance Sheet in Summary, Parent Company
Balance Sheet in Summary, Parent Company Amounts in ' 000 SEK 09/30/2024 09/30/2023 06/30/2024 12/31/2023 Assets Intangible assets 27,692 30,683 28,439 29,935 Tangible assets 6,874 5,755 5,566 5,770 Deferred tax assets 496 733 496 496 Long term receivables from group companies 32,770 37,925 34,079 3
Slide 14: Notes
Notes NOTE 1. ACCOUNTING POLICIES NOTE 3. RISKS AND UNCERTAINTIES The Group applies IFRS Accounting Standards, as adopted by the EU. This interim report has CellaVision is exposed to several risks, which may impact the Group’s development to a greater been prepared in accordance with IAS 34 Interim
Slide 15: Notes, Cont'd
Notes, Cont’d NOTE 5. INTANGIBLE ASSETS NOTE 7. FINANCIAL ASSETS AND LIABILITIES Amounts in ' 000 SEK 09/30/2024 09/30/2023 The disclosed value of financial assets, trade receivables, other receivables, cash and bank, Capitalised expenditure for development 249,434 197,536 trade payables, and other
Slide 16: Reconciliation Tables KPIs, Non-IFRS Measures
Reconciliation Tables KPIs, Non-IFRS Measures The company presents certain financial measures in the Definitions of measures which are not defined according to Gross margin. Gross profit as a percentage of net sales. interim report which are not defined according to IFRS. The IFRS and which are not
Slide 17: Review Report
Review Report To the Board of Directors of CellaVision AB (publ) Corp. id. 556500-0998 Introduction We have reviewed the condensed interim financial information (interim report) of CellaVision AB (publ) as of 30 September 2024 and the nine-month period then ended. The Board of Directors and the Mana
Slide 18: Questions Concerning the Report; Financial Calendar 2025
Questions Concerning the Report Publication This information constitutes information that CellaVision AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 7:20 a.m. CEST on October 24, 2024. CellaVision is listed on the Nasd
Slide 19: This is CellaVision
This is CellaVision About Us Our Strategic Ambition: The power of focus Mission CellaVision is an innovative, global medical technology company Our strategic ambition is to digitalize and improve microscopy To advance laboratory workflow and diagnostic that develops and sells its own leading solutio